Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 1,904 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: AstraZeneca Clear all

Conditions: Central Nervous System Lymphoma
Interventions: Acalabrutinib; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 3
States / cities: Tampa, Florida • Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Glioblastoma, Glioma, Glioblastoma Multiforme, Glioma, Malignant
Interventions: AZD1390; Drug
Lead sponsor: Nader Sanai; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Open Label Run In Esomeprazole, Double Blind Esomeprazole, Double Blind Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Month to 11 Months
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 14
States / cities: Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more

Conditions: Constipation
Interventions: MOVANTIK™ (naloxegol), Sugar Pill; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Coronary Syndrome
Interventions: Ticagrelor, Clopidogrel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 16
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 13 more

Conditions: Diabetes Mellitus
Interventions: Exantide with Dapagliflozin, Exentide, Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 76
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 61 more

Conditions: Pharmacokinetics
Interventions: AZD9742, Diltiazem, ketoconazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 23 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Urothelial Cancer
Interventions: durvalumab, Radiation Therapy; Drug · Radiation
Lead sponsor: Monika Joshi, MD; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 7
States / cities: Iowa City, Iowa • Omaha, Nebraska • New Brunswick, New Jersey + 4 more

Conditions: Mantle Cell Lymphoma (MCL)
Interventions: Acalabrutinib in combination with BR, Acalabrutinib in combination with VR; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 10
States / cities: Louisville, Kentucky • Ann Arbor, Michigan • Hackensack, New Jersey + 6 more

Conditions: Type 2 Diabetes
Interventions: tesaglitazar; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 58
States / cities: Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 55 more

Conditions: Healthy
Interventions: AZD1722, Renvela; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, Onglyza, Dapagliflozin, Farxiga, Glargine insulin, Metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 20
States / cities: Anaheim, California • Los Angeles, California • Miami, Florida + 15 more

Conditions: Severe Hypertriglyceridemia
Interventions: placebo, omefas; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 30
States / cities: National City, California • Sacramento, California • Manchester, Connecticut + 25 more

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Idaho Falls, Idaho • Indianapolis, Indiana

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: AZD2287, AZD2275, AZD2284; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Palo Alto, California • San Diego, California • Miami, Florida + 9 more

Conditions: Peripheral Artery Disease
Interventions: Ticagrelor, Clopidogrel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 130 Years
Enrollment: 13,885 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 290
States / cities: Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 239 more

Conditions: Asthma, Chronic Obstructive Pulmonary Disease COPD
Interventions: AZD7594 inhalation powder (200 μg), AZD7594 inhalation powder (400 μg), AZD7594 pressurized inhalation suspension (200 μg), AZD7594 placebo inhalation powder, AZD7594 placebo pressurized inhalation suspension; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Coronary Atherosclerosis
Interventions: Rosuvastatin, Atorvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 97
States / cities: Huntsville, Alabama • Los Angeles, California • Mountain View, California + 94 more

Conditions: Tourette Syndrome
Interventions: AZD5213 and placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 7
States / cities: Orange, California • St. Petersburg, Florida • Summit, New Jersey + 4 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Mitiperstat (AZD4831), Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 19
States / cities: Newport Beach, California • Clearwater, Florida • DeLand, Florida + 16 more

Conditions: Urinary Bladder Neoplasms
Interventions: Tamoxifen; Drug
Lead sponsor: Seth Lerner; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Coronary Artery Disease
Interventions: Ticagrelor 180mg, Ticagrelor 90mg; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Lupus Nephritis
Interventions: Anifrolumab, Placebo; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 17
States / cities: Glendale, Arizona • Phoenix, Arizona • La Jolla, California + 13 more

Conditions: Gonococcal (GC) Infection
Interventions: Part A, Part B; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas

AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients

Phase 3/Safety & Efficacy of Esomeprazole in Infants

Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy Volunteers

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes

A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

Epanova® for Lowering Very High Triglycerides

Safety and Efficacy of Exenatide as Monotherapy

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

CRESTOR Athero Imaging Head to Head IVUS Study

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment

Impact of Ticagrelor Re-load on Pharmacodynamic Profiles

Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914